Bristol-Myers Squibb Co

Change company Symbol lookup

Select an option...

BMY Bristol-Myers Squibb Co

BOXD Boxed Inc

ALLR Allarity Therapeutics Inc

SIVB SVB Financial Group

LYLT Loyalty Ventures Inc

NMRD Nemaura Medical Inc

LOGI Logitech International SA

BIOC Biocept Inc

KT KT Corp

SVRA Savara Inc

Go

CHARM Therapeutics ("CHARM"), a 3D deep learning biotechnology company discovering and developing transformational medicines, today announced a strategic discovery collaboration with Bristol Myers Squibb (NYSE: BMY) for the identification and...(BusinessWire)

--- $10 million in 2023 grant funding to 17 U.S. organizations focused on addressing social determinants of health --- Expanding aspirational workforce representation goals for those in senior leadership roles (BusinessWire)

Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2023 on Thursday, April 27, 2023. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning...(BusinessWire)

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on May 1, 2023, to...(BusinessWire)

Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and...(BusinessWire)

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted full Marketing Authorization for Reblozyl(R) (luspatercept), a first-in-class therapeutic option, for treatment in adult patients of anemia associated...(BusinessWire)

--First patient has been enrolled in Librexia STROKE trial Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen) today announced the launch...(BusinessWire)

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at Cowen's 43rd Annual Health Care Conference on Tuesday, March 7, 2023. Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Head...(BusinessWire)

--The U.S. Food and Drug Administration has assigned a target action date of October 13, 2023 U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Supplemental Biologics License Application and European Medicines Agency Validates...(BusinessWire)

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research supporting the company's cardiovascular franchise at the American College of Cardiology (ACC) Annual Scientific Session & Expo together with the World Congress of...(BusinessWire)

FinancialNewsMedia.com News Commentary Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of cancer that mainly occurs in white blood cells. White blood cells function for the...(PR Newswire)

--Randomized patients who received Opdivo after radical surgery remained disease-free more than twice as long vs. placebo; patients whose tumor cells express PD-L1 greater-than or equal to1% remained disease-free more than six times as long vs...(BusinessWire)

Kareem Abdul-Jabbar is teaming up with Bristol Myers Squibb and Pfizer to raise awareness of atrial fibrillation (AFib) and its symptoms as part of the No Time to Wait campaign. In support of the campaign, Abdul-Jabbar will share his experience with...(BusinessWire)

--In the pivotal BEYOND study, Reblozyl significantly increased hemoglobin levels, which were sustained over longer time compared to placebo Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP)...(BusinessWire)

--Sotyktu has demonstrated superior efficacy over twice-daily Otezla(R) (apremilast) and placebo in improving skin clearance and symptoms --If approved, Sotyktu would be the first oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor in the...(BusinessWire)

Bristol Myers Squibb (NYSE: BMY) today announced topline results from TRANSCEND CLL 004, a Phase 1/2, open-label, single-arm, multicenter study evaluating Breyanzi (lisocabtagene maraleucel) in adults with relapsed or refractory (R/R) chronic...(BusinessWire)

--Applications Now Open for Physicians and Medical Students The Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) established by the Bristol Myers Squibb Foundation (BMSF) today announced that Amgen, a global...(BusinessWire)

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan's 41st Annual Healthcare Conference on Monday, January 9, 2023. Giovanni Caforio, M.D., Board Chair and Chief Executive Officer will make a formal...(BusinessWire)

Bristol Myers Squibb (NYSE: BMY) has completed the previously announced sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS. The divestiture is part of Bristol Myers Squibb's ongoing evolution of its manufacturing network to...(BusinessWire)